July 27 (Reuters) – AstraZeneca topped second-quarter profit expectations and backed its 2026 forecasts on Monday on demand for its cancer and heart disease therapies, as the drugmaker sought to quell concerns over longer-term growth prospects after a recent trial failure.
(Reporting by Pushkala Aripaka in Bengaluru and Maggie Fick in London, Raechel Thankam Job and Sri Hari N S; Editing by Mrigank Dhaniwala)
Brought to you by www.srnnews.com